Prognostic Impact of Cancer Inflammation Prognostic Index for Non-small Cell Lung Cancer.

IF 4.6 2区医学 Q1 RESPIRATORY SYSTEM

Lung Pub Date : 2023-12-01 Epub Date: 2023-10-31 DOI:10.1007/s00408-023-00649-z

Nozomu Motono, Takaki Mizoguchi, Masahito Ishikawa, Shun Iwai, Yoshihito Iijima, Hidetaka Uramoto

{"title":"Prognostic Impact of Cancer Inflammation Prognostic Index for Non-small Cell Lung Cancer.","authors":"Nozomu Motono, Takaki Mizoguchi, Masahito Ishikawa, Shun Iwai, Yoshihito Iijima, Hidetaka Uramoto","doi":"10.1007/s00408-023-00649-z","DOIUrl":null,"url":null,"abstract":"Purpose: Cancer-inflammation prognostic index (CIPI) is calculated by multiplying the concentration of carcinoembryonic antigen by neutrophil-to-lymphocyte ratio. CIPI has been reported as a prognostic factor for colorectal cancer. Although carcinoembryonic antigen and neutrophil-to-lymphocyte ratio have been reported as prognostic factors for non-small cell lung cancer (NSCLC), it has not been investigated whether CIPI is a useful marker.Methods: We analyzed the prognostic factors, including CIPI, in 700 NSCLC patients treated by pulmonary resection. We also analyzed a subgroup of 482 patients with pathological stage I NSCLC.Result: CIPI > 14.59 (P < 0.01), maximum standardized uptake value (SUVmax) > 5.35 (P < 0.01), lymphatic invasion (P = 0.01), and pathological stage (P < 0.01) were significant factors for relapse-free survival (RFS) in multivariate analysis. SUVmax > 5.35 (P < 0.01) and pathological stage (P < 0.01) were revealed as significant factors for overall survival in the multivariate analysis. In the subanalysis, CIPI > 14.88 (P = 0.01) and SUVmax > 5.07 (P < 0.01) were significant factors for RFS of pathological stage I NSCLC in multivariate analysis.Conclusion: CIPI was a significant factor for RFS in NSCLC patients treated surgically, even in those with pathological stage I disease. SUVmax was also a significant factor for RFS and overall survival in NSCLC patients treated surgically, and for RFS in patients with pathological stage I NSCLC.Trial registration: The Institutional Review Board of Kanazawa Medical University approved the protocol of this retrospective study (Approval Number: I392), and written informed consent was obtained from all patients.","PeriodicalId":18163,"journal":{"name":"Lung","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00408-023-00649-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/31 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Cancer-inflammation prognostic index (CIPI) is calculated by multiplying the concentration of carcinoembryonic antigen by neutrophil-to-lymphocyte ratio. CIPI has been reported as a prognostic factor for colorectal cancer. Although carcinoembryonic antigen and neutrophil-to-lymphocyte ratio have been reported as prognostic factors for non-small cell lung cancer (NSCLC), it has not been investigated whether CIPI is a useful marker.

Methods: We analyzed the prognostic factors, including CIPI, in 700 NSCLC patients treated by pulmonary resection. We also analyzed a subgroup of 482 patients with pathological stage I NSCLC.

Result: CIPI > 14.59 (P < 0.01), maximum standardized uptake value (SUV_max) > 5.35 (P < 0.01), lymphatic invasion (P = 0.01), and pathological stage (P < 0.01) were significant factors for relapse-free survival (RFS) in multivariate analysis. SUV_max > 5.35 (P < 0.01) and pathological stage (P < 0.01) were revealed as significant factors for overall survival in the multivariate analysis. In the subanalysis, CIPI > 14.88 (P = 0.01) and SUV_max > 5.07 (P < 0.01) were significant factors for RFS of pathological stage I NSCLC in multivariate analysis.

Conclusion: CIPI was a significant factor for RFS in NSCLC patients treated surgically, even in those with pathological stage I disease. SUV_max was also a significant factor for RFS and overall survival in NSCLC patients treated surgically, and for RFS in patients with pathological stage I NSCLC.

Trial registration: The Institutional Review Board of Kanazawa Medical University approved the protocol of this retrospective study (Approval Number: I392), and written informed consent was obtained from all patients.

Abstract Image

查看原文本刊更多论文

癌症炎症预后指数对非小细胞肺癌癌症预后的影响。

目的：癌症炎症预后指数（CIPI）是通过将癌胚抗原的浓度乘以中性粒细胞与淋巴细胞的比例来计算的。CIPI已被报道为结直肠癌癌症的预后因素。尽管癌胚抗原和中性粒细胞与淋巴细胞比率已被报道为非小细胞肺癌癌症的预后因素，但尚未研究CIPI是否是有用的标志物。方法：我们分析了700例肺切除的NSCLC患者的预后因素，包括CIPI。我们还分析了482例病理I期NSCLC患者的亚组 > 14.59（P 最大值） > 5.35（P 最大 > 5.35（P 14.88（P = 0.01）和SUVmax > 5.07（P 结论：CIPI是手术治疗NSCLC患者RFS的重要因素，即使在病理I期患者中也是如此。SUVmax也是手术治疗的NSCLC患者RFS和总生存率的重要因素，也是病理I期NSCLC患者的RFS的重要因素。试验注册：金泽医科大学机构审查委员会批准了这项回顾性研究的方案（批准号：I392），并获得了所有患者的书面知情同意书。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lung 医学-呼吸系统

CiteScore

9.10

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Lung publishes original articles, reviews and editorials on all aspects of the healthy and diseased lungs, of the airways, and of breathing. Epidemiological, clinical, pathophysiological, biochemical, and pharmacological studies fall within the scope of the journal. Case reports, short communications and technical notes can be accepted if they are of particular interest.